Raymond Douglas, MD, PhD, of the Cedars-Sinai Medical Center discusses the latest clinical data with teprotumumab to treat patients with thyroid eye disease (TED).
TED is a rare autoimmune disease that can dramatically impact a person’s vision. The condition often occurs in people with hyperthyroidism or Graves’ disease. Common symptoms can include upper eyelid retraction, dry eyes, inflammation, light sensitivity, as well as the sensation of a foreign body present in the eye.
Persons with TED have autoantibodies that activate an IGF-1R-mediated signaling complex on cells within the retro-orbital space. Teprotumumab blocks IGF-1R and is approved to treat persons with TED.
As Dr. Douglas explains in this video, additional data from the clinical trials that led to the approval of teprotumumab were presented at the American Academy of Ophthalmology (AAO) Annual Meeting. Pooled data from Phase 2 and Phase 3 studies showed the drug may also be beneficial in patients with less severe forms of TED while further analysis of the OPTIC trial and its open label OPTIC-X extension study showed the drug to improve double vision in many patients.
To learn more about TED and other autoimmune disorders, click here.